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Intracellular infections caused by invasive pathogens continue to prove diﬃcult to combat, due in part to
the commonly poor membrane permeability of anti-infective drugs. The aim of this study was to
improve the intracellular delivery of one such poorly permeable (but broad-spectrum) anti-infective,
gentamicin. Gentamicin was encapsulated into liposomal nanocarriers which were then surface
functionalized with InvA497, a bacteria-derived invasion protein. Treatment of HEp-2 cells infected with
the enteroinvasive bacteria Yersinia pseudotuberculosis or Salmonella enterica with gentamicin-
containing, InvA497-functionalized liposomes resulted in a signiﬁcantly greater reduction in infection
load than treatment with non-functionalized liposomes, indicating that such a bacteriomimetic
nanocarrier was not only able to promote successful cellular uptake of gentamicin but was also able to
mediate anti-infective drug delivery to both cell cytoplasm and intracellular compartments. The
developed InvA497-functionalized liposomal nanocarrier therefore holds great promise as a strategy for
improving the therapy of intracellular infections.1. Introduction
As clearly demonstrated by the ever-increasing incidence of
‘hard-to-treat’ infections,1 the ability of pathogens to evade
immune detection and resist the action of anti-infective agents
is continually evolving. Eﬀective survival strategies have been
adopted by numerous pathogens, including bacteria such as
Mycobacterium tuberculosis, Staphylococcus aureus and Salmo-
nella enterica. These bacteria invade mammalian cells and take
refuge either in the cytosol, or in other subcellular shelters such
as membrane-bound vacuoles.2 This invasion strategy not only
provides concealment from the host immune system but also
confers protection against anti-infective agents. This is based
on the fact that a considerable number of anti-infective drugs
exhibit either a poor permeability into mammalian cells due to
their high degree of hydrophilicity, or a poor level of intracel-
lular retention.3 Their administration may therefore result inInstitute for Pharmaceutical Research
nfection Research (HZI), Saarbruecken,
holtz-hzi.de
ity, Saarbruecken, Germany
Helmholtz Center for Infection Research
tion (ESI) available. See DOI:
stry, Faculty of Science & Cellular and
oratory (CMBRL), Schulich School of
y, Canada.
9sub-therapeutic intracellular concentrations of anti-infectives,
providing a driving stimulus for the development of bacterial
resistance. Furthermore, the use of high-dose anti-infective
therapies in an eﬀort to increase intracellular drug concentra-
tions may result in adverse or even toxic outcomes.4 The eﬀec-
tive intracellular delivery of anti-infective agents with poor
permeability characteristics therefore clearly constitutes
a considerable and ongoing challenge for the treatment of
infectious diseases.
Encapsulation of anti-infective drugs within nanoscale
delivery systems has been shown to provide a means to enhance
the permeation of these compounds into mammalian cells,
while also allowing for control over drug release kinetics and
minimization of drug-associated side eﬀects.5 Liposomes in
particular, as biocompatible, biodegradable delivery systems,
are reported as being the most commonly utilized nanocarriers
for the intracellular delivery of anti-infectives to date.6,7 A
further enhancement of intracellular access may be achieved by
surface functionalization of nanocarriers such as liposomes
with specic cell-targeting moieties.8 However, despite the
considerable potential for augmentation of nanocarrier-
mediated intracellular delivery through the use of such moie-
ties, as oen demonstrated for example in tumor cell targeting,
surface modication of anti-infective-loaded liposomes with
invasive molecules is not common practice.4 As such, this
remains a strategy to be fully exploited.
In this respect, the use of bacteria-derived proteins known to
mediate cellular adhesion and invasion is of considerableThis journal is © The Royal Society of Chemistry 2016
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View Article Onlineinterest and potential, as functionalization of nanocarriers with
such proteins would allow for exploitation of the natural
mechanisms utilized by invasive bacteria to induce their own
uptake and establish intracellular infection.9 One of the most
well characterized bacteria-derived invasion factors to date is
invasin, an outer membrane protein expressed by members of
the Yersinia spp. (e.g. Y. pseudotuberculosis and Y. enterocolitica)
which mediates bacterial entry into mammalian cells through
interaction with cellular b1 integrin receptors.10–12 Binding of
invasin to cell surface integrin receptors and subsequent
receptor activation leads to a re-organization of the host cell
cytoskeleton and the formation of cytoplasmic protrusions,
ultimately resulting in engulfment of the invasin-expressing
bacterium and intracellular encapsulation within
a membrane-bound vacuole.13,14
Previously, the potential of invasin-functionalized particu-
late nanocarriers to aﬀect intracellular delivery of a model
vaccine antigen has been demonstrated;15,16 surface function-
alization of latex or polystyrene nano- or micro-particles with
invasin has also been shown to facilitate an enhanced uptake of
particles into both phagocytic and non-phagocytic mammalian
cells.8,17–19 A recent study has presented mechanistic insights
into the interaction of invasin-functionalized liposomes with b1
integrin receptor-expressing epithelial cells, and provided
preliminary indications of the eﬃcacy of such a system in
facilitating intracellular anti-infective delivery.20 Yet, in-depth
studies focused on fabrication of anti-infective-loaded,
invasin-functionalized nanocarriers together with detailed
assessment of antimicrobial eﬃcacy against intracellular
pathogens remain to be performed. The current work therefore
aimed to constitute such a study.
To this end, liposomes as highly biocompatible nanocarriers
were rst loaded with gentamicin, a poorly permeable anti-
infective with a broad spectrum of antibacterial action, using
diﬀerent preparation methods in order to achieve optimal drug
loading and system stability. Liposomes were then surface
functionalized with the C-terminal region of invasin (InvA497),
and further characterized. The ability of gentamicin-loaded,
InvA497-functionalized liposomes to deliver gentamicin to the
interior of cells and subcellular compartments was then deter-
mined, by conducting eﬃcacy studies employing the human
epithelial cell line HEp-2 infected with the common entero-
pathogenic bacteria S. enterica and Y. pseudotuberculosis.
2. Experimental
2.1. Liposome preparation and drug loading
Passive loading: lipid lm hydration method. Liposomes
were prepared by the lipid lm hydration (LFH) technique as
previously described.21 Briey, 1,2-dipalmitoyl-sn-glycero-3-
phosphatidylcholine (DPPC, a kind gi from Lipoid GmbH,
Ludwigshafen, Germany), 1,2-dipalmitoyl-sn-glycero-3-phos-
phoethanolamine-N-glutaryl (sodium salt) (DPPE-GA, Avanti
Polar Lipids, Inc. Alabaster, USA) and cholesterol (Sigma
Aldrich, Steinheim, Germany) at a molar ratio of 6 : 0.6 : 3,
together with 10 mg ml1 1,2-dipalmitoyl-sn-glycero-3-phos-
phoethanolamine-N-(lissamine rhodamine B sulfonyl)This journal is © The Royal Society of Chemistry 2016(ammonium salt) (Liss Rhod PE, Avanti Polar Lipids Inc.,
Alabaster, USA), were dissolved in a round-bottomed ask in
a mixture of chloroform and methanol (2 : 1 w/w). The solvent
was evaporated to dryness under reduced pressure at 70 C, 200
mbar and 145 rpm. The formed thin lipid lm was then
hydrated by the addition of 5 ml of either phosphate buﬀered
saline (PBS, pH 7.4) or gentamicin solution (10 mg ml1 in PBS,
Sigma Aldrich, Steinheim, Germany) for 1 h with continual
rotation, in order to form unloaded or gentamicin-loaded
liposomes respectively. Liposomes were then extruded 10
times through 200 nm pore size polycarbonate membranes
(Sartorius, Goettingen, Germany) using a 50 ml extruder (Lip-
osoFast L-50 Avestin, Mannheim, Germany) to facilitate size
reduction. The liposomal dispersion was then diluted 1 : 10
with PBS and stored at 4 C. Liposomal purication was carried
out prior to any further investigations (see ‘Liposome purica-
tion’ below).
Passive loading: microencapsulation vesicle method.
Gentamicin-containing liposomes were also prepared via the
microencapsulation vesicle method (MCV), which involves two
steps: emulsication, followed by dispersion with mechanical
agitation.22 DPPC:DPPE-GA:cholesterol as above were rst dis-
solved in 10 ml of dichloromethane, following which a 5 ml
volume of gentamicin solution (10 mg ml1 in PBS) was added.
The mixture was emulsied with a homogenizer (Polytron PT
2500 E, Eschbach, Germany) at 7000 rpm for 10 min resulting in
the formation of a water-in-oil emulsion. The rst emulsion was
then diluted 1 : 3 in PBS and stirred at 520 rpm and 30 C in
order to form a water-in-oil-in-water emulsion. Stirring was
continued until the organic solvent was completely evaporated
(60 min). The liposomal dispersion was nally extruded,
diluted, stored and later puried as described for the LFH
method.
Active loading: ammonium sulfate liposome method. In the
case of the ammonium sulfate liposome method (ASL), genta-
micin was actively post-loaded into liposomes by the use of a pH
gradient.23,24 A thin lipid lm of DPPC, DPPE-GA and cholesterol
was rst prepared as described for the LFHmethod, followed by
hydration with 5 ml of a 250 mM ammonium sulfate solution
(pH 5.3). Liposomes were then extruded as described above, and
centrifuged at 13 000g for 45 min at 4 C. Pelleted liposomes
were re-suspended in carbonate buﬀer (pH 10.2) containing 10
mg ml1 of gentamicin, and incubated at 37 C for 1 h with
intermittent vortex mixing in order to facilitate gentamicin
loading. Liposome extrusion, dilution, storage and later puri-
cation were carried out as described.2.2. Surface functionalization of liposomes with InvA497
Covalent coupling of InvA497 (produced as described in the
ESI†) to LFH liposomal surfaces was performed as described
previously.20,25 Briey, 2 ml of LFH liposomal suspension was
incubated for a minimum of 3 h with a crosslinking reagent
solution, consisting of N-(3-dimethylaminopropyl)-N0-ethyl-
carbodiimide hydrochloride (EDC, 48 mM, Sigma Aldrich,
Steinheim, Germany) and N-hydroxysuccinimide (NHS, 19 mM,
Carbolution Chemicals, Saarbruecken, Germany) in an ice bathRSC Adv., 2016, 6, 41622–41629 | 41623
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View Article Onlinewith gentle mixing. Liposomes were then washed (described
below) to remove excess crosslinking reagent. A volume of 300
ml of InvA497 (1 mg ml1 in PBS) was then added, followed by
incubation in an ice bath overnight with gentle mixing. Further
washing of liposomes was then carried out to remove non-
conjugated invasin.
2.3. Liposome purication
Purication of liposomes was carried out by centrifugal ultra-
ltration using Centrisart® tubes (Sartorius, Goettingen, Ger-
many) equipped with a 300 000 molecular weight cut oﬀ
(MWCO) membrane. Briey, the liposomal suspension was
placed into a Centrisart® tube followed by the ltration
membrane, and centrifuged at 3720g and 4 C for 30 min. The
ultra-ltrate was then removed and the liposomes were re-
suspended in fresh PBS buﬀer. In all cases, 3 purication
cycles were performed to ensure the complete removal of any
residual non-liposomal material.
2.4. Physical characterization
The size distribution and zeta potential of liposomes were
measured by photon correlation spectroscopy and electropho-
retic mobility respectively, using a Zetasizer Nano ZS (Malvern
Instruments, Worcestershire, UK). In all cases liposomes were
dispersed in PBS pH 7.4 prior to measurement, and measure-
ments were conducted at 25 C.
2.5. Gentamicin encapsulation eﬃciency and loading
capacity
A uorometric method based on the use of o-phthaldialdehyde
reagent (OPA, Sigma Aldrich, Steinheim, Germany) was used to
quantify gentamicin encapsulated within liposomes. Genta-
micin was rst extracted from liposomal nanocarriers and
processed for analysis by treatment with OPA as previously
described.26 The uorescence of processed samples was then
measured on a uorimeter (Tecan Innite M200, Maennedorf,
Switzerland) at an excitation wavelength of 344 nm and an
emission wavelength of 450 nm. The amount of gentamicin
contained within samples was determined with reference to
standards and used to calculate nanocarrier encapsulation
eﬃciency;27 liposomal gentamicin content was also employed
together with the total amount of liposomal lipid content
(determined as described in the ESI†) in order to calculate
loading capacity.28
2.6. Quantication of InvA497 functionalization
The amount of InvA497 coupled to liposomal surfaces was
quantied using a bicinchoninic acid protein assay (BCA) kit, in
accordance with the instructions of the manufacturer (Sigma
Aldrich, Steinheim, Germany). The amount of surface-coupled
InvA497 was quantied by measurement of UV absorbance at
562 nm in reference to created standard curves, and expressed
as a functionalization eﬃciency (%) relative to the initial
amount of InvA497 added.29 A loading ratio (coupled
InvA497 : liposomal lipid content, % w/w) was also calculated.41624 | RSC Adv., 2016, 6, 41622–416292.7. Gentamicin release kinetics
The in vitro release behavior of gentamicin from liposomes was
investigated using a dialysis-based method.30 Briey, following
verication with gentamicin solutions that drug transport was
not a limiting factor in the employed dialysis setup, samples of
gentamicin-containing liposomes either with or without
InvA497 surface functionalization (each containing 0.325 mg
gentamicin) were added to 10 000 MWCO dialysis bags (Spec-
trum Laboratories Inc., California, USA). Bags were sealed and
suspended in 30 ml of PBS (pH 7.4) as release medium, at 37 C
with continuous shaking. At predetermined time intervals, 1 ml
of PBS was withdrawn for analysis of gentamicin content and
replaced with an equal volume of fresh PBS. Cumulative release
of gentamicin was then calculated by quantication of genta-
micin in removed PBS aliquots, using the OPA uorometric
method described above.2.8. Cell culture
Cells of the human larynx carcinoma-derived HEp-2 cell line
were cultured in a 75 cm2 ask using Roswell Park Memorial
Institute (RPMI 1640) medium (Gibco, Paisley, UK), supple-
mented with 7.5% newborn calf serum (NCS). Cells were incu-
bated in a humidied incubator (Heraeus CO2 Thermo
Scientic Incubator) at 37 C and 5% CO2. Medium was
changed every two days and cells were split upon conuency.2.9. Determination of anti-infective eﬃcacy
Optimization of cellular invasion assay conditions. HEp-2
cells infected with either S. enterica serovar Typhimurium
SL1344 or Y. pseudotuberculosis YPIII serotype O:3 strain were
used as an in vitro model to evaluate the internalization and
resulting eﬃcacy of InvA497-functionalized, gentamicin-loaded
liposomes. Optimal experimental parameters for achievement
of intracellularly-infected HEp-2 cells were identied as
described in detail in the ESI.†
Liposomal treatment of infected cells. To determine the
impact of InvA497-functionalization on gentamicin-loaded
liposome eﬃcacy, infected HEp-2 cells prepared as described
above and in the ESI† were incubated for 1 h with gentamicin-
containing, InvA497-functionalized or non-functionalized lipo-
somes (50 mg ml1 gentamicin) suspended in binding buﬀer
(see ESI†). Following two washing steps in PBS, cell lysates were
produced by treatment with 200 ml lysis buﬀer containing 0.1%
Triton X-100. Lysates were then plated on sterile agar plates in
serial dilutions and incubated overnight at 37 C in the case of
S. enterica, and for 48 h at 25 C for Y. pseudotuberculosis.
Following incubation, bacterial colonies were counted and
multiplied by appropriate dilution factors. The nal number of
colony forming units (CFU) calculated from each cell lysate was
expressed as a percentage of remaining intracellular bacteria
(relative to the CFU of bacteria used for initial infection – the
inoculum). In the case of each nanocarrier treatment group,
this value was then normalized to the percentage of remaining
intracellular bacteria in untreated cell samples, and expressed
as a percentage of bacterial killing.This journal is © The Royal Society of Chemistry 2016
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View Article Online2.10. Statistical analysis
Where appropriate, data are shown as mean standard error of
the mean (SEM) from at least three independent experiments.
One way ANOVA followed by post hoc analysis or Student's t-test
were performed where relevant to determine the statistical
signicance of any observed diﬀerences. Diﬀerences were
considered to be signicant (*) at a p-value <0.05.
3. Results
3.1. Physical characteristics
In order to investigate the optimal method for production of
gentamicin-loaded liposomes, nanocarriers were prepared
using three diﬀerent production procedures. Passive loading of
gentamicin by liposomal preparation via the LFH method
resulted in liposomes with a mean initial size of approximately
202 nm (Fig. 1A and S1A†). Liposomes prepared with the MCV
method, also utilizing passive drug loading, had a size of
approximately 137 nm, while a slightly larger mean liposomal
size (approximately 244 nm) was seen following active loading
of gentamicin using the ASL method (Fig. 1A). The poly-
dispersity index (PDI) of all three preparations was below 0.2
(Fig. 1B) and a highly negative surface charge was also noted
initially in all cases (Fig. 1C). The three preparations were then
stored at 4 C and evaluated over time in order to provide an
assessment of colloidal stability; no appreciable change in size,
PDI and zeta potential was noted for any of the nanocarriers
over a period of 21 days (Fig. 1A–C).
3.2. Encapsulation eﬃciency and loading capacity
The extent of liposome drug encapsulation and loading was also
determined initially and monitored over time. LFH liposo-
mes showed the highest initial encapsulation eﬃciency ofFig. 1 (A) Size, (B) polydispersity index (PDI) and (C) zeta potential of
liposomes produced by lipid ﬁlm hydration (LFH), microencapsulation
vesicle (MCV) and ammonium sulfate liposome (ASL) methods were
measured at day 0, day 15, and day 21. Values represent the mean 
SEM values from three independent preparations.
This journal is © The Royal Society of Chemistry 2016approximately 43%, which was signicantly higher than that of
the ASL liposomes, while the encapsulation eﬃciency of MCV
was approximately 33% (Fig. 2A). In contrast to the encapsula-
tion eﬃciency, the initial loading capacity of ASL liposomes
appeared to be the highest of the three preparations at
approximately 34% – however, this was not a statistically
signicant result. No signicant diﬀerence was also noted
between the initial loading capacity of LFH liposomes (30%)
and MCV liposomes (25%) (Fig. 2B). Aer 15 days, both the
encapsulation eﬃciency and loading capacity of LFH liposomes
had decreased, to approximately 15% and 11% respectively,
while only 5% encapsulation eﬃciency and 2% loading capacity
were found for MCV liposomes at the same time point.
Surprisingly, the ASL preparation was not found to contain any
gentamicin aer 15 days. At day 21, only the LFH liposomes
were seen to retain gentamicin, with no drug detected in MCV
and ASL preparations.
As the LFH liposomes showed the highest encapsulation
eﬃciency and the greatest ability to sustain gentamicin encap-
sulation over time, this preparation was utilized for further
experiments.
3.3. Characterization of InvA497-functionalized liposomes
Gentamicin-loaded LFH liposomes functionalized with InvA497
were subjected to initial characterization followed by a short-
term stability study. Results showed homogeneously sized
liposomes of approximately 198 nm in diameter, with a zeta
potential of approximately 23 mV (Fig. 3 and S1B†). These
characteristics were similar to those of non-functionalized
liposomes, meaning that the functionalization process did not
have an appreciable eﬀect on liposome colloidal properties.
Aer 7 days of storage, the size, PDI and zeta potential of
InvA497-functionalized liposomes showed no signicant
changes (Fig. 3A–C). The eﬃciency of carbodiimide-mediated
crosslinking of InvA497 to liposomal surfaces was measured
via a BCA assay, with results conrmed by SDS-PAGE (data not
shown). An initial InvA497 functionalization eﬃciency of
approximately 60% was found (Fig. 3D), while the ratio of
coupled InvA497 to total liposomal lipid content (% w/w) was
approximately 17%. InvA497 functionalization of liposomes was
seen to result in a considerable reduction in gentamicin
encapsulation eﬃciency, from approximately 40% for non-Fig. 2 Stability of liposome encapsulation eﬃciency (A) and loading
capacity (B) at day 0, day 15 and day 21. Values represent the mean 
SEM values from three independent preparations. Signiﬁcance was
deﬁned as * ¼ p value <0.05.
RSC Adv., 2016, 6, 41622–41629 | 41625
Fig. 3 Colloidal stability after functionalization was evaluated by
measuring size (A), polydispersity index (PDI) (B) and zeta potential (C)
at days 0, 2 and 7. Chemical stability was evaluated by measurement of
the stability of gentamicin encapsulation eﬃciency (bars) and InvA497
functionalization eﬃciency (lines) (D). Results represent mean  SEM
of three independent preparations.
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View Article Onlinefunctionalized liposomes (Fig. 2A, LFH) to approximately 15%
for functionalized liposomes (Fig. 3D). The encapsulation eﬃ-
ciency at day 2 decreased to 7%, and further to 5% aer 7 days.
The functionalization eﬃciency was also seen to drop upon
storage (Fig. 3D).3.4. Gentamicin release kinetics
The kinetics of gentamicin release from non-functionalized
gentamicin-loaded liposomes (GL) and InvA497-functionalized
gentamicin loaded liposomes (I-GL) dispersed in PBS at physi-
ological temperature was investigated (Fig. 4). An initial burst
release of gentamicin was seen upon dispersion in PBS. As
a result, approximately 65% of the originally entrapped genta-
micin was released from both GL and I-GL nanocarriers within
a period of 3 h. No signicant diﬀerence in release from GL andFig. 4 In vitro release proﬁle of gentamicin from liposomes func-
tionalized with InvA497 (I-GL) or without surface functionalization
(GL), over a 24 h time period. The inset graph shows release over the
ﬁrst 3 h. Data represent the mean of 3 independent replicate experi-
ments, while error bars are representative of SEM values.
41626 | RSC Adv., 2016, 6, 41622–41629I-GL nanocarriers was however noted, indicating that the
functionalization procedure had no eﬀect on gentamicin
release kinetics.3.5. Determination of anti-infective eﬃcacy
Optimization of cellular invasion assay conditions. Epithe-
lial cells of the HEp-2 cell line were rst infected with S. enterica
or Y. pseudotuberculosis using various diﬀerent invasion and
incubation conditions, in order to screen for a range of
parameters resulting in promising levels of intracellular inva-
sion for further optimization (Fig. S2†). Parameters deemed to
be promising in initial studies were then evaluated in further
invasion assays, to determine the optimum conditions for
establishment of intracellular infection in the current model.
These subsequent invasion experiments revealed that a multi-
plicity of infection (MOI, ratio of bacteria : HEp-2 cells) of 10
with 1 h of infection time and 1 h of gentamicin solution
treatment for extracellular bacteria killing (EBK) resulted in the
highest cell invasion load for S. enterica (Fig. 5A). For Y. pseu-
dotuberculosis, employment of an MOI of 25 together with 1 h
infection time and 1 h of EBK resulted in a similar invasion
percentage to that of an MOI of 10, with 1 h infection time and 1
h EBK (Fig. 5B). Thus, for the conduction of anti-infective eﬃ-
cacy studies, invasion conditions of an MOI of 10, 1 h infection
time and 1 h of EBK were chosen for S. enterica, while an MOI
equal to 25 (in order to maximize the number of bacteria) with
1 h infection time and 1 h of EBK was chosen for optimal
Y. pseudotuberculosis invasion.
Liposomal treatment. HEp-2 cells containing either S.
enterica or Y. pseudotuberculosis were treated with freshly-
prepared I-GL or GL (both at 50 mg ml1 gentamicin) for 1 h.
In both cases, a negligible bacterial killing was noted with drug
free, InvA497-functionalized liposomes, employed as a control
(data not shown). A 22% reduction of the intracellular bacterial
load was seen following treatment of both S. enterica-infected
(Fig. 6A) and Y. pseudotuberculosis-infected (Fig. 6B) cells with
the I-GL nanocarriers – such a level of bacterial killing was
signicantly greater than that resulting from treatment of
infected cells with the non-functionalized, GL nanocarriers.Fig. 5 Percentage of recovered intracellular S. enterica (A) and Y.
pseudotuberculosis (B) after infection of HEp-2 cells at MOIs of 10 and
25 respectively, followed in all cases by 1 h infection time (Inf), and an
extracellular bacteria killing (EBK) of either 1 or 2 h. Data represent the
mean  SEM of three independent preparations.
This journal is © The Royal Society of Chemistry 2016
Fig. 6 HEp-2 cells infected with S. enterica (A) or Y. pseudotubercu-
losis (B) treated with gentamicin liposomes (GL) and InvA497-func-
tionalized gentamicin liposomes (I-GL). Data for bacterial killing are
normalized to values of untreated cells. Values represent the mean 
SEM from three independent experiments. Signiﬁcance was deﬁned as
* ¼ p value <0.05.
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View Article Online4. Discussion
4.1. Physico-chemical characteristics of liposomal
nanocarriers
In the current work, liposomes loaded with the poorly perme-
able anti-infective gentamicin were formulated in order to
facilitate drug penetration into mammalian epithelial cells,
allowing for targeting of invasive, intracellular bacteria. Three
diﬀerent preparation methods were initially utilized for the
production of gentamicin-loaded liposomes: two methods in
which gentamicin was passively loaded during vesicle forma-
tion (LFH and MCV), and a third method in which drug was
actively incorporated into liposomes post-production (ASL).
Liposomes prepared by each method were monitored with
respect to both their colloidal and chemical characteristics, in
order to determine which nanocarrier system exhibited the
most favorable properties both initially and over time. This
comparison of preparation approaches was deemed to be an
important rst step as hydrophilic drugs such as gentamicin are
notoriously diﬃcult to retain within nanocarriers, having the
tendency to escape rapidly to the external aqueous phase during
and/or following the particle preparation process.31–33 Lipo-
somes prepared via the LFH technique were selected for further
use following such investigation, as in addition to favorable
colloidal properties (exhibited in fact by all produced liposomal
nanocarriers), LFH liposomes showed the highest initial
encapsulation eﬃciency and the greatest capacity to sustain
incorporation of gentamicin over time upon storage – impor-
tant points of distinction considering subsequent functionali-
zation of liposomes with InvA497 would necessitate several
incubation periods, in addition to washing cycles. The obtained
results are in agreement with published literature, where it has
been shown that passive loading of liposomes with gentamicin
is preferable to active loading, due to the resulting higher
amounts of entrapped drug and drug-to-lipid ratio.34 Additional
insight is however provided by the current work, which, by
conducting a direct comparison of LFH and MCV methodolo-
gies, has shown that the specic selection of passive loading
method is also important in order to maximize liposomal drug
encapsulation and loading.
Liposomes prepared by the LFH method were then
successfully surface-functionalized with the aforementionedThis journal is © The Royal Society of Chemistry 2016InvA497, a C-terminal fragment of the Y. pseudotuberculosis
outer membrane protein invasin.10 The size, PDI and zeta
potential of InvA497-functionalized liposomes were similar to
that of non-functionalized liposomes; however, the functional-
ization procedure was seen to have a noticeable eﬀect on the
gentamicin encapsulation eﬃciency, which dropped from
approximately 40% to approximately 15%. This decrease, likely
due to the mentioned multiple washing steps required and
employed during the functionalization procedure, is neverthe-
less still higher than what has been found previously in some
cases using the LFH method,34–36 and was not deemed as being
prohibitive to the conduction of further studies. The function-
alized liposomal nanocarriers showed a colloidal stability over
one week, while the amount of the encapsulated drug was seen
to decrease over this period. A focus is therefore currently being
placed on optimization of the functionalization protocol;
freshly prepared liposomes were meanwhile utilized for all
further studies in the currently presented work in order to have
maximal drug incorporation.
In addition to the capacity of functionalized and non-
functionalized liposomes to retain encapsulated gentamicin
on storage, the kinetics of gentamicin release from such
nanocarriers in more physiologically-relevant conditions was
also of interest. The in vitro release kinetics of gentamicin from
liposomes either functionalized or not functionalized with
invasin – I-GL and GL respectively – were therefore investigated.
Approximately 65% of the total liposomal gentamicin was seen
to be released from both liposomal nanocarriers within 3 h,
indicative of both a relatively rapid release mechanism and
a lack of eﬀect of surface-bound InvA497 on release kinetics.
This burst release of gentamicin was not expected to have an
adverse impact on testing of nanocarrier systems in eﬃcacy
studies however, as the employment of relatively shorter
liposome-cell incubation periods was anticipated.4.2. Anti-infective eﬃcacy studies
As mentioned previously, while the strategy of using actively-
targeted nanocarriers to facilitate translocation of incorpo-
rated actives across biological membranes is widely discussed
in literature, such a strategy is more commonly employed in the
context of tumor therapy37,38 than for intracellular delivery of
anti-infectives. The use of invasin-functionalized nanocarriers
for intracellular anti-infective delivery is also not a commonly
employed strategy – as has been referred to earlier, the majority
of literature to date reports on the potential of invasin to
improve uptake of unloaded carrier systems, with eﬃcacy
assessment of invasin-functionalized carriers loaded with any
form of active being seldom undertaken.18,39 The use of InvA497-
functionalized liposomes for the intracellular delivery of
gentamicin was therefore considered to be a strategy of great
interest for exploration; it was also deemed of the utmost
importance to investigate the ability of I-GL to facilitate eﬀective
intracellular delivery of gentamicin, following thorough char-
acterization of the properties of this nanocarrier system. For
this purpose, HEp-2 cells infected with the enteroinvasive
bacteria S. enterica or Y. pseudotuberculosis were employed. TheRSC Adv., 2016, 6, 41622–41629 | 41627
RSC Advances Paper
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
0 
A
pr
il 
20
16
. D
ow
nl
oa
de
d 
on
 0
2/
06
/2
01
7 
11
:1
1:
11
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Onlineuse of these two invasive bacteria allowed for testing of the
ability of I-GL to access various intracellular compartments:
once inside cells, Y. pseudotuberculosis remains within vacu-
oles,40whereas S. enterica intracellular infection is characterized
by both vacuolar and cytosolic replication.41
An optimized bacterial invasion protocol was rst estab-
lished, in order to determine anMOI level and durations of both
bacterial incubation and extracellular bacterial killing which
would not result in an overwhelming intracellular bacterial load
(Fig. S2,† and 5). Of interest and importance to note is the use of
gentamicin in solution in the context of this initial bacterial
invasion step, in order to exclusively kill any extracellularly
located bacteria, rather than as a test formulation in the
subsequent eﬃcacy studies themselves. The employment of
such a ‘gentamicin protection assay’42 has found common
usage in invasion protocols,43 due to the fact that bacteria which
have successfully invaded mammalian cells are ‘protected’ from
the poorly permeable free drug, while extracellularly-located
bacteria are not.12,44 Such a poor permeability was indeed
conrmed in the subsequent eﬃcacy testing stage of the current
study: no killing of intracellular bacteria was noted to occur in
the untreated control group, in which cells had been pre-treated
with gentamicin solution for extracellular bacterial killing, fol-
lowed by incubation with drug- and liposome-free binding
buﬀer. A variation on this control, in which cells were pre-
treated with gentamicin solution followed by incubation with
gentamicin-containing binding buﬀer, also resulted in a negli-
gible reduction of intracellular bacteria (data not shown).
Gentamicin was therefore considered as an ideal cargo for
eﬃcacy testing of the current functionalized nanocarrier.
In the context of the eﬃcacy testing studies themselves, HEp-
2 cells containing either S. enterica or Y. pseudotuberculosis were
treated with I-GL or GL, in order to investigate the impact of
liposome functionalization on intracellular delivery and activity
of gentamicin. In both S. enterica-infected (Fig. 6A) and
Y. pseudotuberculosis-infected (Fig. 6B) HEp-2 cells, treatment
with I-GL nanocarriers was seen to aﬀect a signicantly greater
level of bacterial killing than treatment with GL nanocarriers.
Such an observation is consistent with the previously observed
greater uptake of invasin-functionalized liposomes by HEp-2
cells,20 in comparison to liposomes without surface-bound
invasin. A greater eﬀect was in fact expected as a result of
treatment with GL, as gentamicin-loaded liposomes in the
absence of functionalization have previously been shown to be
eﬀective in the killing of intracellular bacteria; however, this
eﬀective action has generally been seen in infected phagocytic
cell models, such as macrophages.35 As demonstrated in the
current work, entry of non-functionalized liposomal nano-
carriers into non-phagocytic, epithelial cells appears to present
a much greater challenge, and therefore requires the presence
of further invasive moieties.
The noted ability of I-GL nanocarriers to reduce the intra-
cellular bacteria load in infected cells indicates that InvA497-
functionalized liposomes are not only able to invade into
epithelial cells, but are also able to release their poorly-
permeable payload once inside cells in order to exert a bacteri-
cidal eﬀect. Furthermore, the eﬀective killing of both S. enterica41628 | RSC Adv., 2016, 6, 41622–41629(cytoplasmic/vacuolar bacterium) and Y. pseudotuberculosis
(vacuolar bacterium) demonstrates that gentamicin contained
within the invasin-functionalized liposomal nanocarriers is
able to be transported across both vacuolar membranes in order
to reach bacteria enclosed within these sub-cellular compart-
ments, and is also able to gain access to the cytosol. This is
a promising observation, and could form the basis of future
mechanistic studies as well as further investigations to deter-
mine the cell–liposome incubation time resulting in maximal
reduction in infection load. An extension of the incubation
period of Yersinia-infected cells with I-GL from 1 to 2 h has
already been shown to result in a greater bacterial killing,20 an
encouraging observation for conduction of further optimization
studies.5. Conclusions
In this study, liposomal nanocarriers loaded with gentamicin
were successfully prepared via three diﬀerent methods: the LFH
method, the MCV method and the ASL method. All three
methods resulted in liposome preparations exhibiting
a homogenous size of approximately 200 nm and a negative
surface charge. Of these three types of gentamicin-loaded
liposomes, LFH liposomes showed the highest encapsulation
eﬃciency and stability and were therefore used further to
prepare InvA497-functionalized, gentamicin-containing lipo-
somes. Surface-functionalized gentamicin liposomes were able
to reduce the infection load of both S. enterica and Y. pseudo-
tuberculosis in infected epithelial cells, meaning that such
a nanocarrier was successful not only in delivering gentamicin
across epithelial cell membranes, but also into vacuolar
compartments. This bacteriomimetic nanocarrier system
therefore represents a promising approach for intracellular
delivery of poorly permeable anti-infective drugs.Acknowledgements
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